Mocht u kanker-actueel de moeite waard vinden en ons willen ondersteunen om kanker-actueel online te houden dan kunt u ons machtigen voor een periodieke donatie via donaties: https://kanker-actueel.nl/NL/donaties.html of doneer al of niet anoniem op - rekeningnummer NL79 RABO 0372931138 t.n.v. Stichting Gezondheid Actueel in Amersfoort. Onze IBANcode is NL79 RABO 0372 9311 38
Elk bedrag is welkom. En we zijn een ANBI instelling dus uw donatie of gift is in principe aftrekbaar voor de belasting.
12 december 2016: Bron: United European Gastroenterol J. 2016 Aug; 4(4): 546–561. Published online 2015 Nov 13.
Uit een grote review studie van 19 gerandomiseerde studies (totaal bij 2730 mensen) blijkt dat bepaalde strengen van probiotica - melkzuurbacteriën effectief zijn in het bestrijden van de Helicobacter pylori en ook effectief de bijwerkingen vermindert van een anti-biotica kuur tegen de Helicobacter pylori. Voor wie het nog niet weet de Helicobacter pylori is voor 90 procent verantwoordelijk voor het ontstaan van maagkanker.
Belangrijk dus als iemand de Helicobacter pylori bij zich draagt deze zo snel mogelijk te elimineren. Zie ook deze studie: https://kanker-actueel.nl/NL/Helicobacter_pylori_bacterie_elinineren_voorkomt_maagkanker.html
Tekst gaat verder onder grafiek
Hier de gebruikte vormen van bepaalde strengen probiotica - mlekzxuurbacteriën en de effecten daarvan.
Table 1.
Characteristics of H. pylori eradication and probiotic treatments by type of probiotic mixture.
| Probiotic mix | Eradication therapy | Duration eradication (weeks) | Daily probiotic dose (cfu/d) | Probiotic form | Duration probiotic treatment (weeks) | Follow-up post-treatment (weeks) | Reference by first author |
|---|---|---|---|---|---|---|---|
| L. acidophilus La5 + B. animalis subsp. lactis Bb12 | ACL | 1 | 1 × 1010 | Yogurt | 4 | 4–8 | Sheu, 200238 |
| L. acidophilus La5 + B. animalis subsp. lactis Bb12 | AMO + Bs | 1 | 4 × 1011 | Yogurt | 4 | 18 | Sheu, 200639 |
| L. acidophilus La5 + B. animalis subsp. lactis Bb12 | ACO | 1 | 7.5 × 108 | Drink | 5 | 3 | DeVrese, 201140 |
| L. acidophilus + B. animalis subsp. lactis | CRT | 1 | 1 × 1010 | Sachet | 2 | 5–7 | Cremonini, 200225 |
| L. acidophilus + B. bifidum, nr | AE, then CET | 1.4 | 7 × 109 | Drink | 1.4 | 8–10 | Manfredi, 201224 |
| L. acidophilus + B. bifidum + lactoferrin, nr | AE, then CET | 1.4 | 7 × 109 | Drink | 1.4 | 8–10 | Manfredi, 201224 |
| L. acidophilus La5 + B. bifidum 12 | ACP | 1 | 2 × 106 | Yogurt | 1 | 4 | Mirzaee, 201241 |
| L. acidophilus La5 + B. bifidum 12 | A/M, CO | 2 | 1–2 × 108 | Sachet | 6 | 0 | Wang, 201442 |
| L. helveticus + L. rhamnosus, nr | AC + PPI (nr) | 1.4 | 6 × 109 | Capsule | 2.9 | 7 | Plewinska, 200643 |
| L. helveticus R0052 + L. rhamnosus R011 | ACP | 1.4 | 8 × 109 | Capsule | 2.9 | 1.4 | Ziemniak, 200644 |
| L. helveticus R0052 + L. rhamnosus R011 | ACR | 1 | 1.2 × 1010 | Capsule | 2.9 | 4 | Babak, 200745 |
| L. helveticus R0052 + L. rhamnosus R011 | ACO | 1 | 8 × 109 | Capsule | 1.4 | 4–6 | Vdovychenko, 200846 |
| L acidophilus HY2177 + L. casei HY2743 + B. longum HY8001 | AC + PPI (nr) | 1 | 1.5 × 1010 | Yogurt | 3 | 4 | Kim, 200847 |
| L acidophilus HY2177 + L. casei HY2743 + B. longum HY8001 | AEM | 2 | 1.2 × 106 | Yogurt | 4 | 4 | Yoon, 201126 |
| L. acidophilus + B. longum + Entero. faecalis, nr | AMO + Bs | 2 | 2 × 107 | Capsule | 2 | 4 | Cao, 200548 |
| L. acidophilus + B. longum + Entero. faecalis, nr | ECO | 1 | 2 × 107 | Capsule | 1 | 4 | Huang, 200849 |
| L. acidophilus + B. longum + Entero. faecalis, nr | AMP | 1 | 2 × 107 | Capsule | 1 | 4 | Wen, 201050 |
| L. acidophilus + B. longum + Entero. faecalis, nr | AR then CRT, then R | 5.4 | 2 × 107 | Capsule | 5.4 | 0 | He, 201151 |
| Eight-strain mix | ACE | 1 | 4 × 1010 | Sachet | 1 | 8 | De Bortoli, 200752 |
| Eight-strain mix | ACO | 1 | 2 × 1010 | Sachet | 1 | 4 | Tolone, 201253 |
A: amoxicillin; B., Bifidobacterium; Bs: bismuth sulfate; C: clarithromycin; E: esomeprazole; Entero., Enterococcus; L: lansoprazole; L., Lactobacillus; M: metronidazole; nr: strain or PPI type not reported in paper/abstract; O: omeprazole; P: pantoprazole; PPI: proton-pump inhibitor; R: rabeprozole; T: tinidazole.
Eight-strain mix contains: L. acidophilus, L. casei rhamnosus, L. plantarum, L. reuteri, L. salivarius, L. sporogenes, B. infantis, B. longum.
Ik ga verder maar niet in op de resultaten want het volledige studierapport: Systematic review and meta-analysis: Multi-strain probiotics as adjunct therapy for Helicobacter pylori eradication and prevention of adverse events is gratis in te zien met ook interessante referentielijst.
Het abstract staat onder dit artikel.
Naast probiotica - melkzuurbacteriën zijn er andere middelen zoals groene thee die de Heliobacter Pylori kan bestrijden. Zie o.a. deze recente review studie met groene thee: Green tea inhibits Helicobacter growth in vivo and in vitro
Ook bepaalde Chinese kruiden kunnen de helicobacter pylori elimineren, zie daarvoor o.a. deze studie: https://kanker-actueel.nl/NL/voeding-en-voedingstoffen-behandeling-met-qingwei-zhitong-vermindert-uitgebreidheid-maagzweren-veroorzaakt-door-helicobacter-pylori-de-bacterie-verdween-bovendien-bij-47-van-de-patienten-in-de-behandelde-groep.html
Hier het abstract van de probiotica review studie:
Our meta-analysis found adjunctive use of some multi-strain probiotics may improve H. pylori eradication rates and prevent the development of adverse events and antibiotic-associated diarrhea, but not all mixtures were effective.
United European Gastroenterol J. 2016 Aug; 4(4): 546–561.
Published online 2015 Nov 13. doi: 10.1177/2050640615617358
PMCID: PMC4971786
Systematic review and meta-analysis: Multi-strain probiotics as adjunct therapy for Helicobacter pylori eradication and prevention of adverse events
1 Abstract
Background
Eradication rates with triple therapy for Helicobacter pylori infections have currently declined to unacceptable levels worldwide. Newer quadruple therapies are burdened with a high rate of adverse events. Whether multi-strain probiotics can improve eradication rates or diminish adverse events remains uncertain.
Methods
Relevant publications in which patients with H. pylori infections were randomized to a multi-strain probiotic or control were identified in PubMed, Cochrane Databases, and other sources from 1 January 1960–3 June 2015. Primary outcomes included eradication rates, incidence of any adverse event and the incidence of antibiotic-associated diarrhea. As probiotic efficacy is strain-specific, pooled relative risks and 95% confidence intervals were calculated using meta-analysis stratified by similar multi-strain probiotic mixtures.
Results
A total of 19 randomized controlled trials (20 treatment arms, n = 2730) assessing one of six mixtures of strains of probiotics were included. Four multi-strain probiotics significantly improved H. pylori eradication rates, five significantly prevented any adverse reactions and three significantly reduced antibiotic-associated diarrhea. Only two probiotic mixtures (Lactobacillus acidophilus/Bifidobacterium animalis and an eight-strain mixture) had significant efficacy for all three outcomes.
Conclusions
Our meta-analysis found adjunctive use of some multi-strain probiotics may improve H. pylori eradication rates and prevent the development of adverse events and antibiotic-associated diarrhea, but not all mixtures were effective.
References
1. Papamichael K, Mantzaris GJ. Pathogenesis of Helicobacter pylori infection: Colonization, virulence factors of the bacterium and immune and non-immune host response. Nosokom Chron 2012; 7: 32–37.
2. Malfertheiner P, Link A, Selgrad M. Helicobacter pylori: Perspectives and time trends. Nat Rev Gastroenterol Hepatol 2014; 11: 628–638. [PubMed]
3. Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1984; 1: 1311–1315. [PubMed]
4. Ford AC, Forman D, Hunt RH, et al. Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: Systematic review and meta-analysis of randomised controlled trials. Br Med J 2014; 348: g3174–g3174. [PMC free article] [PubMed]
5. Gisbert JP, Calvet X. Review article: The effectiveness of standard triple therapy for Helicobacter pylori has not changed over the last decade, but it is not good enough. Aliment Pharmacol Ther 2011; 34: 1255–1268. [PubMed]
6. Ierardi E, Giorgio F, Losurdo G, et al. How antibiotic resistances could change H.. pylori treatment: A matter of geography? World J Gastroenterol 2013; 19: 8168–8180. [PMC free article] [PubMed]
7. Yang JC, Lu CW, Lin CJ. Treatment of Helicobacter pylori infection: Current status and future concepts. World J Gastroenterol 2014; 20: 5283–5293. [PMC free article] [PubMed]
8. Delchier JC, Malfertheiner P, Thieroff-Ekerdt R. Use of a combination formulation of bismuth, metronidazole and tetracycline with omeprazole as a rescue therapy for eradication of H. pylori. Aliment Pharmacol Ther 2014; 40: 171–177. [PubMed]
9. Gatta L, Vakil N, Vaira D. Global eradication rates for Helicobacter pylori infection: Systematic review and meta-analysis of sequential therapy. Br Med J 2013; 347: f4587–f4587. [PMC free article] [PubMed]
10. Malfertheiner P, Megraud F, O'Morain CA, et al. Management of Helicobacter pylori infection – the Maastricht IV/Florence Consensus Report. Gut 2012; 61: 646–664. [PubMed]
11. Gisbert JP, Romano M, Gravina AG, et al. Helicobacter pylori second-line rescue therapy with levofloxacin- and bismuth-containing quadruple therapy, after failure of standard triple or non-bismuth quadruple treatments. Aliment Pharmacol Ther 2015; 41: 768–775. [PubMed]
12. Jheng GH, Wu IC, Shih HY, et al. Comparison of second-line quadruple therapies with or without bismuth for H. pylori infection. Biomed Res Int 2015; 2015: 163960–163960. [PMC free article] [PubMed]
13. Masoodi M, Talebi-Taher M, Tabatabaie K, et al. Clarithromycin vs. gemifloxacin in quadruple therapy regimens for empiric primary treatment of H. pylori infection: A randomized clinical trial. Middle East J Dig Dis 2015; 7: 88–93. [PMC free article] [PubMed]
14. Megraud F, Coenen S, Versporten A, et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut 2013; 62: 34–42. [PubMed]
15. Wilhelm SM, Johnson JL, Kale-Pradhan PB. Treating bugs with bugs: The role of probiotics as adjunctive therapy for Helicobacter pylori. Ann Pharmacother 2011; 45: 960–966. [PubMed]
16. McFarland LV. Application of meta-analysis to specific research fields: Lessons learned. World J Meta-analysis 2015; 3: 188–192.
17. McFarland LV, Goh S. Preventing pediatric antibiotic-associated diarrhea and Clostridium difficile infections with probiotics: A meta-analysis. World J Meta-analysis 2013; 1: 102–120.
18. Hill C, Guarner F, Reid G, et al. Expert consensus document: The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol 2014; 11: 506–514. [PubMed]
19. Sakarya S, Gunay N. Saccharomyces boulardii expresses neuraminidase activity selective for α2,3-linked sialic acid that decreases Helicobacter pylori adhesion to host cells. APMIS 2014; 122: 941–950. [PubMed]
20. Hongying F, Xianbo W, Fang Y, et al. Oral immunization with recombinant Lactobacillus acidophilus expressing the adhesin Hp0410 of Helicobacter pylori induces mucosal and systemic immune responses. Clin Vaccine Immunol 2014; 21: 126–132. [PMC free article] [PubMed]
21. Myllyluoma E, Ahonen AM, Korpela R, et al. Effects of multispecies probiotic combination on Helicobacter pylori infection in vitro. Clin Vaccine Immunol 2008; 15: 1472–1482. [PMC free article] [PubMed]
22. Yang YJ, Sheu BS. Probiotics-containing yogurts suppress Helicobacter pylori load and modify immune response and intestinal microbiota in the Helicobacter pylori-infected children. Helicobacter 2012; 17: 297–304. [PubMed]
23. Fujimura S, Watanabe A, Kimura K, et al. Probiotic mechanism of Lactobacillus gasseri OLL2716 strain against Helicobacter pylori. J Clin Microbiol 2012; 50: 1134–1136. [PMC free article] [PubMed]
24. Manfredi M, Bizzarri B, Sacchero RI, et al. Helicobacter pylori infection in clinical practice: Probiotics and a combination of probiotics and lactoferrin improve compliance, but not eradication, in sequential therapy. Helicobacter 2012; 17: 254–263. [PubMed]
25. Cremonini F, Di Caro S, Covino M, et al. Effect of different probiotic preparations on anti-Helicobacter pylori therapy-related side effects: A parallel group, triple blind, placebo-controlled study. Am J Gastroenterol 2002; 97: 2744–2749. [PubMed]
26. Yoon H, Kim N, Kim JY, et al. Effects of multi-strain probiotic-containing yogurt on second-line triple therapy for Helicobacter pylori infection. J Gastroenterol Hepatol 2011; 26: 44–48. [PubMed]
27. Navarro-Rodriguez T, Silva FM, Barbuti RC, et al. Association of a probiotic to a Helicobacter pylori eradication regimen does not increase efficacy or decreases the adverse effects of the treatment: A prospective, randomized, double-blind, placebo-controlled study. BMC Gastroenterol 2013; 13: 56–56. [PMC free article] [PubMed]
28. McFarland LV, Malfertheiner P, Huang Y, et al. Meta-analysis of single strain probiotics for the eradication of Helicobacter pylori and prevention of adverse events. World J Meta-analysis 2015; 3: 97–117.
29. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: Explanation and elaboration. Br Med J 2009; 339: e1–e34. [PMC free article] [PubMed]
30. Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 2015; 4: 1–9. [PMC free article] [PubMed]
31. Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: Elaboration and explanation. Br Med J 2015; 349: g7647–g7647. [PubMed]
32. Higgins JPT and Green S (eds). Cochrane handbook for systematic reviews of interventions. Version 5.1.0. The Cochrane Collaboration, www.cochrane-handbook.org (March 2011, accessed 7 January 2015).
33. Moher D, Hopewell S, Schulz KF, et al. CONSORT 2010 explanation and elaboration: Updated guidelines for reporting parallel group randomized trials. J Clin Epidemiol 2010; 63: e1–e37. [PubMed]
34. Sun X, Briel M, Walter S, et al. Is a subgroup effect believable? Updating criteria to evaluate the credibility of subgroup analysis. Br Med J 2010; 340: 850–854. [PubMed]
35. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. Br Med J 1997; 315: 629–634. [PMC free article] [PubMed]
36. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 50: 1088–1101. [PubMed]
37. Peters JL, Sutton AJ, Jones DR, et al. Comparison of two methods to detect publication bias in meta-analysis. JAMA 2006; 295: 676–680. [PubMed]
38. Sheu BS, Wu JJ, Lo CY, et al. Impact of supplement with Lactobacillus- and Bifidobacterium containing yogurt on triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther 2002; 16: 1669–1675. [PubMed]
39. Sheu BS, Cheng HC, Kao AW, et al. Pretreatment with Lactobacillus- and Bifidobacterium-containing yogurt can improve the efficacy of quadruple therapy in eradicating residual Helicobacter pylori infection after failed triple therapy. Am J Clin Nutr 2006; 83: 864–869. [PubMed]
40. de Vrese M, Kristen H, Rautenberg P, et al. Probiotic lactobacilli and bifidobacteria in a fermented milk product with added fruit preparation reduce antibiotic associated diarrhea and Helicobacter pylori activity. J Dairy Res 2011; 78: 396–403. [PubMed]
41. Mirzaee V, Rezahosseini O. Randomized control trial: Comparison of Triple Therapy plus Probiotic Yogurt vs. Standard Triple Therapy on Helicobacter pylori Eradication. Iran Red Crescent Med J 2012; 14: 657–666. [PMC free article] [PubMed]
42. Wang YH, Huang Y. Effect of Lactobacillus acidophilus and Bifidobacterium bifidum supplementation to standard triple therapy on Helicobacter pylori eradication and dynamic changes in intestinal flora. World J Microbiol Biotechnol 2014; 30: 847–853. [PubMed]
43. Plewinska E, Planeta-Malecka I, Bak-Romaniszyn L, et al. Probiotics in the treatment of Helicobacter pylori infection in children (Polish). Gastroenterol Pol 2006; 13: 315–319.
44. Ziemniak W. Efficacy of Helicobacter pylori eradication taking into account its resistance to antibiotics. J Physiol Pharmacol 2006; 57: 123–141. [PubMed]
45. Babak OY, Malaya LT. The use of Lacidofil in treatment of duodenal peptic ulcers associated with H. pylori. (Ukrainian). News of Pharmacy and Medicine 2007; 5: 24–25.
46. Vdovychenko VL, Demidova AL, Bidyuk OA. Efficiency of quadrotherapy with probiotics in patients with duodenal peptic ulcer (Ukrainian). Modern Gastroenterol 2008; 5: 90–92.
47. Kim MN, Kim N, Lee SH, et al. The effects of probiotics on PPI-triple therapy for Helicobacter pylori eradication. Helicobacter 2008; 13: 261–268. [PubMed]
48. Cao YJ, Qu CM, Yuan Q, et al. Control of intestinal flora alteration induced by eradication therapy of Helicobacter pylori infection in the elders. Chin J Gastroenterol Hepatol 2005; 14: 195–199.
49. Huang JY, Cao HB, Shi BY. Efficacy of bifid combining triple regimen on Helicobacter pylori eradication. Shanghai Med Pharm J 2008; 12: 552–554.
50. Wen JJ, Qiu RF. Clinical study in efficacy of bifid combining triple regimen on Helicobacter pylori eradication. J Gannan Med Univ 2010; 30: 902–903.
51. He XM, Li BS, Li YJ. Bifid triple viable facilitates the sequential therapy for Helicobacter pylori eradication. Mod Digestion Intervent 2011; 2: 90–92.
52. de Bortoli N, Leonardi G, Ciancia E, et al. Helicobacter pylori eradication: A randomized prospective study of triple therapy versus triple therapy plus lactoferrin and probiotics. Am J Gastroenterol 2007; 102: 951–956. [PubMed]
53. Tolone S, Pellino V, Vitaliti G, et al. Evaluation of Helicobacter pylori eradication in pediatric patients by triple therapy plus lactoferrin and probiotics compared to triple therapy alone. Ital J Pediatr 2012; 38: 63–63. [PMC free article] [PubMed]
54. McFarland LV. Deciphering meta-analytic results: A mini-review of probiotics for the prevention of paediatric antibiotic-associated diarrhea and Clostridium difficile infections. Benef Microbes 2014; 2: 1–6. [PubMed]
55. Lee SY. Current progress toward eradicating Helicobacter pylori in East Asian countries: Differences in the 2013 revised guidelines between China, Japan, and South Korea. World J Gastroenterol 2014; 20: 1493–1502. [PMC free article] [PubMed]
56. Graham DY. Editorial-avoiding unethical H. pylori clinical trials: Susceptibility-based studies and probiotics as adjuvants. Helicobacter 2015; 20: 321–325. [PMC free article] [PubMed]
57. Dang Y, Reinhardt JD, Zhou X, et al. The effect of probiotics supplementation on Helicobacter pylori eradication rates and side effects during eradication therapy: A meta-analysis. PLoS One 2014; 9: e111030–e111030. [PMC free article] [PubMed]
58. Sachdeva A, Nagpal J. Effect of fermented milk-based probiotic preparations on Helicobacter pylori eradication: A systematic review and meta-analysis of randomized-controlled trials. Eur J Gastroenterol Hepatol 2009; 21: 45–53. [PubMed]
59. Zou J, Dong J, Yu X. Meta-analysis: Lactobacillus containing quadruple therapy versus standard triple first-line therapy for Helicobacter pylori eradication. Helicobacter 2009; 14: 97–107. [PubMed]
60. Wang ZH, Gao QY, Fang JY. Meta-analysis of the efficacy and safety of Lactobacillus-containing and Bifidobacterium-containing probiotic compound preparation in Helicobacter pylori eradication therapy. J Clin Gastroenterol 2013; 47: 25–32. [PubMed]
61. Pacifico L, Osborn JF, Bonci E, et al. C. Probiotics for the treatment of Helicobacter pylori infection in children. World J Gastroenterol 2014; 20: 673–683. [PMC free article] [PubMed]
62. Li S, Huang XL, Sui JZ, et al. Meta-analysis of randomized controlled trials on the efficacy of probiotics in Helicobacter pylori eradication therapy in children. Eur J Pediatr 2014; 173: 153–161. [PubMed]
63. Szajewska H. Pooling data on different probiotics is not appropriate to assess the efficacy of probiotics. Eur J Pediatr 2014; 173: 975–975. [PMC free article] [PubMed]
64. Lv Z, Wang B, Zhou X, et al. Efficacy and safety of probiotics as adjuvant agents for Helicobacter pylori infection: A meta-analysis. Exp Ther Med 2015; 9: 707–716. [PMC free article] [PubMed]
65. Zheng X, Lyu L, Mei Z. Lactobacillus-containing probiotic supplementation increases Helicobacter pylori eradication rate: Evidence from a meta-analysis. Rev Esp Enferm Dig 2013; 105: 445–453. [PubMed]
66. Zhang MM, Qian W, Qin YY, et al. Probiotics in Helicobacter pylori eradication therapy: A systematic review and meta-analysis. World J Gastroenterol 2015; 21: 4345–4357. [PMC free article] [PubMed]
67. Wang KY, Ki SN, Liu CS, et al. Effects of ingesting Lactobacillus and Bifidobacterium-containing yogurt in subjects with colonized Helicobacter pylori. Am J Clin Nutri 2004; 80: 737–741. [PubMed]
68. Cruchet S, Obregon MC, Salazar G, et al. Effect of the ingestion of a dietary product containing Lactobacillus johnsonii La1 on Helicobacter pylori colonization in children. Nutrition 2003; 19: 716–721. [PubMed]
69. Rosania R, Minenna MF, Giorgio F, et al. Probiotic multistrain treatment may eradicate Helicobacter pylori from the stomach of dyspeptics: A placebo-controlled pilot study. Inflamm Allergy Drug Targets 2012; 11: 244–249. [PubMed]
70. Johnston BC, Supina AL, Ospina M, et al. Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database Syst Rev 2007; 2: CD004827–CD004827. [PubMed]
71. Shen J, Zuo Z, Mao A. Effect of probiotics on inducing remission and maintaining therapy in ulcerative colitis, Crohn's disease, and pouchitis: Meta-analysis of randomized controlled trials. Inflamm Bowel Dis 2014; 20: 21–35. [PubMed]
Articles from United European Gastroenterology Journal are provided here courtesy of SAGE Publications
Plaats een reactie ...
1 Reactie op "Probiotica - melkzuurbacterien bestrijdt succesvol Helicobacter pylori en zorgt voor veel minder bijwerkingen van anti-biotica bij bestrijding van Helicobacter pylori"
Gerelateerde artikelen
- Probiotica - melkzuurbacteriën doden in korte tijd helft van Helicobactor Pylori bacteriënkolonie bij muizen en geneest en voorkomt ontstekingen in de darmen en voorstadia van darmkanker. Artikel geplaatst april 2005
- Probiotica melkzuurbacteriëen: een overzicht van studies en artikelen over toepassing van probiotica naast behandelingen van kanker en herstel van darmflora na belastende behandelingen
Graag reactie jesenmel@live.nl
Ik kom niet er echt wijs uit hier.
Mvg Cindy